| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.13 | 0.008 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | 0.086 | 0.01 |
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.077 | 0.01 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | 0.082 | 0.01 |
| mRNA | manumycin A | CTRPv2 | pan-cancer | AAC | -0.078 | 0.02 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | -0.09 | 0.02 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.02 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.35 | 0.02 |